Identification of Risk Allels for Prostate Cancer
NCT00323388 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2024-01-11
Summary
Identification of Risk Allels for Prostate Cancer
Conditions
Sponsors & Collaborators
-
University of New Mexico
lead OTHER
Principal Investigators
-
John Scariano · University of New Mexico
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-11-30
- Primary Completion
- 2007-09-30
- Completion
- 2007-09-30
Countries
- United States
Study Locations
More Related Trials
-
Precision Medicine in the Prostate Cancer Care Pathway
NCT04763317 ·Status: RECRUITING
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence
NCT02070575 ·Status: COMPLETED
-
Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
NCT02370355 ·Status: TERMINATED
-
Molecular Mechanisms Underlying Prostate Cancer Disparities
NCT02229565 ·Status: COMPLETED
-
Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer
NCT03103321 ·Status: COMPLETED ·Phase: PHASE3
-
Irish Programme for Stratified Prostate Cancer Therapy
NCT03162003 ·Status: COMPLETED
-
Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program
NCT00035217 ·Status: COMPLETED
-
Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients
NCT01705652 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing
NCT03511235 ·Status: COMPLETED
-
Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)
NCT03296124 ·Status: WITHDRAWN
-
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NCT03009981 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Prolaris Value and Efficacy
NCT03152448 ·Status: TERMINATED
-
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
NCT00002924 ·Status: COMPLETED
-
Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154
NCT00535834 ·Status: COMPLETED
-
Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA
NCT01521949 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
NCT00984919 ·Status: COMPLETED
-
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole
NCT01275651 ·Status: WITHDRAWN
-
Cilengitide in Treating Patients With Prostate Cancer
NCT00121238 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
NCT00967954 ·Status: UNKNOWN ·Phase: NA
-
Oral Colchicine in Men With Castrate Resistant Prostate Cancer
NCT01481233 ·Status: WITHDRAWN ·Phase: PHASE2
-
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515 ·Status: RECRUITING ·Phase: PHASE2
-
Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
NCT02757365 ·Status: UNKNOWN ·Phase: PHASE4
-
Pioneering Advances in Care and Education (PACE)
NCT03397160 ·Status: COMPLETED ·Phase: NA
-
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
NCT01420861 ·Status: TERMINATED ·Phase: PHASE2